Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
ALGS•First participant dosed in China Phase 1 study
Aligos Therapeutics, Inc. said the first participant has been dosed in the Phase 1 study of its potentially best-in-class antisense oligonucleotide ALG-170675 by its partner Amoytop in China.
Aug. 12 (Reuters) - Aligos Therapeutics, Inc. (ALGS.O):
- ALIGOS THERAPEUTICS ANNOUNCES FIRST PARTICIPANT DOSED IN THE PHASE 1 STUDY OF ITS POTENTIALLY BEST-IN-CLASS ANTISENSE OLIGONUCLEOTIDE ALG-170675 BY ITS PARTNER AMOYTOP IN CHINA
